Litcius/Paper detail

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry

Lieneke F.M. Ariëns, Jorien van der Schaft, Lotte S. Spekhorst, Daphne S. Bakker, Geertruida L. E. Romeijn, T. Kouwenhoven, Marijke Kamsteeg, Angelique N. Voorberg, Albert J. Oosting, Ilona de Ridder, Annemieke Sloeserwij, Inge Haeck, Judith L. Thijs, Marie L. A. Schuttelaar, Marjolein de Bruin‐Weller

2020Journal of the American Academy of Dermatology91 citationsDOIOpen Access PDF

Topics & Concepts

MedicineDupilumabAtopic dermatitisRefractory (planetary science)CohortDermatologyTerm (time)Cohort studyFamily medicinePediatricsInternal medicinePhysicsQuantum mechanicsAstrobiologyDermatology and Skin DiseasesAllergic Rhinitis and SensitizationAsthma and respiratory diseases
Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry | Litcius